CEO of Neem Biotech, Dr. Graham Dixon discusses the presentations at the American Society for Microbiology (ASM) Conference on Biofilms and the North American Cystic Fibrosis (NACF) Conference on a new way to enhance antibiotic effectiveness by reducing biofilms and bacterial virulence more broadly for the development of novel antimicrobial treatments for infections in chronic wounds and chronic respiratory infections including cystic fibrosis.
Dr. Graham Dixon is Neem’s Chief Executive Officer. He brings with him over 25 years of experience in nurturing biotechnology companies and guiding their novel compounds into and through the clinic. With a PhD in biochemistry from Swansea University, his R&D track record spans VC-led and publicly-funded biotechnology and pharmaceutical companies in the UK and Europe more broadly.
Previous experience includes: Onxeo – CSO, Head of R&D; Sensorium – CSO, Head of R&D; Addex – CSO, Head of R&D; and Galapagos – CSO/SVP R&D.